Detection of minimal residual disease by circulating tumour DNA and risk of recurrence in Stage I–III colorectal cancer: the CITCCA study

作者
Cecilia Merk,Sofia Birkeälv,Rickard Strandberg,Rebecka Bergström,Girish V. Putcha,Markus Mayrhofer,Karen Howarth,Johan Lindberg,Anna Martling
出处
期刊:British Journal of Surgery [Oxford University Press]
卷期号:113 (Supplement_9)
标识
DOI:10.1093/bjs/znag093.030
摘要

Abstract Introduction Recurrence after curative-intent therapy remains a major challenge in colorectal cancer (CRC) and a leading cause of cancer-related death. Novel biomarkers are needed to enable detection of molecular residual disease (MRD) and support individualized treatment decisions. Circulating tumour DNA (ctDNA) has shown potential as a promising biomarker for MRD detection and recurrence risk stratification. Methods In this prospective multicentre study, patients with stage I–III CRC undergoing curative-intent treatment, were enrolled across 7 Swedish centres between 2020 and 2024. Surveillance included CT and CEA at 1 and 3 years. ctDNA was analysed using a tumour-informed, structural variant–based assay. Plasma samples were obtained preoperatively and postoperatively at 4–6 weeks, 3 and 6 months, 1 and 2 years. The primary endpoint was the association between ctDNA and recurrence-free interval (RFI). Results In total, 398 patients (239 colon, 159 rectal cancer) with a median age of 69 years (29–83) were included. Postoperative ctDNA positivity at any time was strongly associated with recurrence (HR 33.97; 95% c.i. 16.98–67.97), including both colon (HR 32.33; 95% c.i. 12.81–81.62) and rectal cancer (HR 104.46; 95% c.i. 22.66–481.54). Three-year RFI after definitive treatment was 21% (95% c.i. 10–46%) for ctDNA-positive patients compared with 91% (95% c.i. 86–96%) for ctDNA-negative patients. Among patients with positive ctDNA at 4–6 weeks, omission of ACT was associated with worse outcomes (2-year RFI 42 versus 61%). Discussion This nationwide study confirms the prognostic significance of ctDNA in colon cancer and adds new evidence supporting its clinical relevance in rectal cancer, highlighting its potential for personalized treatment decisions.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王人捷发布了新的文献求助30
1秒前
搜集达人的应助被追寻夏槐采纳,获得20
1秒前
BIGDUCK完成签到,获得积分10
2秒前
FashionBoy的应助被vc采纳,获得10
2秒前
3秒前
4秒前
GG酱发布了新的文献求助30
4秒前
酷波er的应助被眼睛大初之采纳,获得10
5秒前
6秒前
田様的应助被鹦鹉采纳,获得10
6秒前
黄橙橙完成签到 ,获得积分10
7秒前
7秒前
syvshc的应助被含蓄的冰绿采纳,获得10
8秒前
lucky完成签到 ,获得积分10
9秒前
9秒前
10秒前
Ferry完成签到,获得积分10
11秒前
11秒前
JH_Yang发布了新的文献求助10
12秒前
Nole的应助被hannah采纳,获得10
13秒前
zZZZ发布了新的文献求助10
14秒前
14秒前
Ryan发布了新的文献求助10
14秒前
15秒前
西红柿发布了新的文献求助10
15秒前
123发布了新的文献求助10
15秒前
欢呼半山完成签到 ,获得积分10
15秒前
16秒前
16秒前
桐桐的应助被清水烫春菜采纳,获得10
18秒前
Ava的应助被酷酷的悒采纳,获得10
18秒前
18秒前
科研通AI6.2的应助被12采纳,获得10
18秒前
19秒前
20秒前
21秒前
开心小懒虫完成签到,获得积分10
21秒前
Lucas的应助被科研通管家采纳,获得10
22秒前
123564的应助被科研通管家采纳,获得10
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192776
求助须知:如何正确求助?哪些是违规求助? 9579206
关于积分的说明 21864151
捐赠科研通 7792348
什么是DOI,文献DOI怎么找? 3437041
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483916